A comparison of the mRECIST and RECIST criteria in the efficacy assessment of systemic chemotherapy in patients with hepatocellular carcinoma
10.3760/cma.j.issn.1007-8118.2019.06.003
- VernacularTitle:两种实体瘤疗效评价标准对肝细胞癌患者系统化疗效果评价的比较
- Author:
Honghu JIN
1
;
Changying ZHAO
;
Zhen ZHANG
;
Wei HU
;
Chunhua LI
Author Information
1. 湖北医药学院附属东风医院肝胆胰外科
- Keywords:
Carcinoma,hepatocellular;
Response evaluation criteria in solid tumors;
Antineoplastic combined chemotherapy protocols
- From:
Chinese Journal of Hepatobiliary Surgery
2019;25(6):411-414
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the efficacy of the solid tumor evaluation criteria 1.1 (RECIST 1.1) and the revised solid tumor efficacy evaluation criteria (mRECIST) after chemotherapy in the hepatocellular carcinoma system.Methord Retrospective analysis of 34 patients with advanced hepatocellular carcinoma who underwent Folfox4 system chemotherapy from the Department of Hepatobiliary and Pancreatic Surgery of Dongfeng Hospital affiliated to Hubei Medical College from July 2017 to July 2018,including 24 males and 10 females.Spiral CT and/or MRI (four-phase) scans were performed 1 nonth,2 months,and every 2 months after treatment,and the effects were evaluated by RECIST 1.1 and mRECIST,respectively.The survival curve was drawn by Kaplan-Meier method,and log-rank test was used to compare survival curves.Result In 34 patients evaluated with the RECIST 1.1 criteria,0 patient showed complete remission (CR),6 patients partial remission (PR),20 patients stable disease (SD),and 8 patients progressive disease (PD).Using the mRECIST criteria,CR:0,PR:10,SD:17,and PD:7 patients.The Kappa value of the two methods was 0.271,95％ CI:0.010 ～0.535.The log-rank test showed that there was no significant difference in the survival curves of patients between PR,SD and PD in RECIST 1.1 (P ＞ 0.05).The cumulative survival rates were 40.0％,11.8％ and 0,respectively.The survival curves of patients with PR,SD and PD in mRECIST were statistically significant (P ＜ 0.05),and the cumulative survival rates were 37.5％,0,and 0,respectively.Conclusion The mRECIST criteria were more suitable than the RECIST 1.1 criteria in assessing efficacy of systemic chemotherapy for hepatocellular carcinoma.
